<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027547</url>
  </required_header>
  <id_info>
    <org_study_id>1586.00</org_study_id>
    <secondary_id>FHCRC-1586.00</secondary_id>
    <secondary_id>NCI-H01-0080</secondary_id>
    <secondary_id>CDR0000069042</secondary_id>
    <nct_id>NCT00027547</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Sibling Donors For Treatment Of Patients With High Risk Acute Lymphocytic Leukemia In Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may be able to replace&#xD;
      immune cells that were destroyed by chemotherapy and radiation therapy. Sometimes the&#xD;
      transplanted cells are rejected by the body's normal tissues. Mycophenolate mofetil and donor&#xD;
      white blood cells may prevent this from happening.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to determine the effectiveness of combination chemotherapy and&#xD;
      total-body irradiation followed by peripheral stem cell transplantation in treating patients&#xD;
      who have acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine if a one-year disease free survival of 40% and a day 200 transplant-related&#xD;
           mortality of less than 25% can be achieved in patients with high-risk acute&#xD;
           lymphoblastic leukemia in complete remission treated with a nonmyeloablative&#xD;
           conditioning regimen comprising fludarabine and total body irradiation followed by&#xD;
           allogeneic peripheral blood stem cell or bone marrow transplantation.&#xD;
&#xD;
        -  Evaluate the efficacy and toxicity of donor lymphocyte infusion in the treatment of&#xD;
           minimal residual disease after nonmyeloablative allografting in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive a nonmyeloablative conditioning regimen comprising fludarabine IV on days -4&#xD;
      to -2 and total body irradiation (TBI) on day 0. Children undergo allogeneic peripheral blood&#xD;
      stem cell transplantation (PBSCT) or bone marrow transplantation after TBI on day 0. Adults&#xD;
      undergo filgrastim (G-CSF)-mobilized allogeneic PBSCT after TBI on day 0.&#xD;
&#xD;
      Patients also receive graft-versus-host disease (GVHD) prophylaxis therapy comprising oral&#xD;
      cyclosporine twice daily on days -3 to 56 and then tapered and oral mycophenolate mofetil&#xD;
      once at 5-10 hours after transplantation on day 0 and then twice daily on days 1-27.&#xD;
&#xD;
      Patients who have no evidence of grade 2 or greater acute GVHD or clinically extensive&#xD;
      chronic GVHD, have been off GVHD prophylaxis therapy for 1-2 weeks, and have stable or&#xD;
      increasing minimal residual disease after discontinuation of GVHD prophylaxis therapy receive&#xD;
      donor lymphocyte infusion (DLI) IV over 30 minutes. DLI repeats every 4 weeks for a total of&#xD;
      3 doses (if necessary).&#xD;
&#xD;
      Patients without a history of CNS leukemia and patients with a history of CNS leukemia&#xD;
      previously treated with prophylactic craniospinal irradiation receive methotrexate (MTX) or&#xD;
      cytarabine (ARA-C) intrathecally (IT) for a total of 2 doses before transplantation and for a&#xD;
      total of 6 doses beginning on day 32 after transplantation. Patients with a history of CNS&#xD;
      leukemia not previously treated with craniospinal irradiation undergo craniospinal&#xD;
      irradiation for 11 days before conditioning regimen and then MTX or ARA-C IT for a total of 6&#xD;
      doses beginning on day 32 after transplantation. Male patients also undergo testicular&#xD;
      radiotherapy for 7 days.&#xD;
&#xD;
      Patients are followed at 1, 2, 3, 6, 12, 18, and 24 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients (20 adults and 10 children) will be accrued for&#xD;
      this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acute lymphoblastic leukemia (ALL)&#xD;
&#xD;
          -  Adult patients must meet 1 of the following criteria:&#xD;
&#xD;
               -  Age 50 to 75 with high-risk ALL in complete remission (CR) (less than 5% blasts&#xD;
                  by morphology on bone marrow aspirate and absence of peripheral blasts) or ALL in&#xD;
                  second CR (CR2) or greater&#xD;
&#xD;
               -  Age 18 to 50 with high-risk ALL in first CR (CR1) and either ineligible for&#xD;
                  conventional allogeneic transplantation (based on general medical condition) or&#xD;
                  refused conventional transplantation&#xD;
&#xD;
                    -  High-risk adult ALL in CR1 includes patients meeting 1 or more of the&#xD;
                       following criteria:&#xD;
&#xD;
                         -  Age 30 and over&#xD;
&#xD;
                         -  Non-T-cell phenotype&#xD;
&#xD;
                         -  Cytogenetic abnormalities including t(9;22), t(4;11), trisomy 8, or&#xD;
                            monosomy 7&#xD;
&#xD;
                         -  Failure to achieve CR after 4 weeks of induction chemotherapy&#xD;
&#xD;
               -  Age 18 to 50 with ALL in CR2 or greater and ineligible for conventional&#xD;
                  allogeneic transplantation based on general medical condition&#xD;
&#xD;
               -  Age 18 to 50 with high-risk ALL in CR2 or greater and refused conventional&#xD;
                  allogeneic transplantation&#xD;
&#xD;
          -  Pediatric patients must meet 1 of the following criteria:&#xD;
&#xD;
               -  Under age 18 with high-risk ALL in CR1 and ineligible for conventional allogeneic&#xD;
                  transplantation based on general medical condition&#xD;
&#xD;
                    -  High-risk pediatric ALL in CR1 includes patients meeting 1 or more of the&#xD;
                       following criteria:&#xD;
&#xD;
                         -  Cytogenetic abnormalities&#xD;
&#xD;
                              -  t(9;22) with WBC at least 25,000/mm3 at diagnosis&#xD;
&#xD;
                              -  t(4;11) in patients under age 1 or age 10 and over&#xD;
&#xD;
                              -  Hypodiploidy (no more than 45 chromosomes)&#xD;
&#xD;
                         -  Failure to achieve CR after 4 weeks of induction chemotherapy&#xD;
&#xD;
                         -  Persistent peripheral blasts after 1 week of induction chemotherapy&#xD;
&#xD;
               -  Under age 18 with CR2 or greater and ineligible for conventional allogeneic&#xD;
                  transplantation based on general medical condition&#xD;
&#xD;
               -  Age 12 and under allowed if approved by the principle investigator&#xD;
&#xD;
          -  No active CNS disease&#xD;
&#xD;
          -  Availability of a sibling donor (excluding an identical twin)&#xD;
&#xD;
               -  HLA genotypically identical for at least 1 haplotype&#xD;
&#xD;
               -  HLA-A, -B, -C, -DRB1, and -DQB1 genotypically or phenotypically identical&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  75 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 50-100% (adults)&#xD;
&#xD;
          -  Lansky 40-100% (children)&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No fulminant liver failure&#xD;
&#xD;
          -  No alcoholic hepatitis&#xD;
&#xD;
          -  No history of bleeding esophageal varices&#xD;
&#xD;
          -  No grade II or greater hepatic encephalopathy&#xD;
&#xD;
          -  No hepatic synthetic dysfunction evidenced by prolongation of PT with INR greater than&#xD;
             2.5&#xD;
&#xD;
          -  No intractable ascites related to portal hypertension&#xD;
&#xD;
          -  No bacterial or fungal liver abscess&#xD;
&#xD;
          -  No chronic viral hepatitis with bilirubin greater than 5 mg/dL&#xD;
&#xD;
          -  No biliary obstruction with bilirubin greater than 5 mg/dL&#xD;
&#xD;
          -  No concurrent symptomatic biliary disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac ejection fraction at least 30%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No requirement for supplementary continuous oxygen&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 year after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent posttransplantation growth factors during mycophenolate mofetil&#xD;
             administration&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Georges, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2011</last_update_posted>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

